(MORE) Dow Jones Newswires
07-07-03 1327ET
STAMFORD -(Dow Jones)- Novogen Ltd.'s (NVGN) said preliminary data from a London study showed its Promensil is a natural alternative for minimizing vaginal dryness in postmenopausal women.
In a press release Monday, the Australian drug maker said 80 milligrams of Promensil may help alleviate sexual discomfort in women at midlife.
The trial, conducted at King's College Hospital in London, had 29 participants between 45 and 65 years old. It was designed to evaluate the effectiveness and safety of the natural dietary isoflavone supplement derived from red clover. Promensil was compared with placebo and no side effects were reported.
The preliminary findings are encouraging for women who want to manage menopause naturally and to continue enjoying sex, said Malcolm Whitehead, director of King's College Hospital's gynecology and endocrinology unit, in the release.
Nasdaq shares of Novogen recently traded at $17.40, up 36 cents, or 2.1%, on volume of 60,895 shares. The company has an average daily volume of 56,482 shares.
Company Web site: http://www.novogen.com
-Eamon Beltran; Dow Jones Newswires; 201-938-5400
(MORE) Dow Jones Newswires07-07-03 1327ET STAMFORD -(Dow Jones)-...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)